Qiagen N.V.

NYSE:QGEN Voorraadrapport

Marktkapitalisatie: US$9.7b

Qiagen Beheer

Beheer criteriumcontroles 4/4

De CEO Qiagen is Thierry Bernard, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.99M, bestaande uit 49.1% salaris en 50.9% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.14% van de aandelen van het bedrijf, ter waarde $ 14.01M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.8 jaar en 9.6 jaar.

Belangrijke informatie

Thierry Bernard

Algemeen directeur

US$2.0m

Totale compensatie

Percentage CEO-salaris49.1%
Dienstverband CEO5.1yrs
Eigendom CEO0.1%
Management gemiddelde ambtstermijn6.8yrs
Gemiddelde ambtstermijn bestuur9.6yrs

Recente managementupdates

Recent updates

Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

Oct 11
Some Confidence Is Lacking In Qiagen N.V.'s (NYSE:QGEN) P/S

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

Sep 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 32% Undervalued

With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

May 21
With Qiagen N.V. (NYSE:QGEN) It Looks Like You'll Get What You Pay For

Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

May 03
Qiagen N.V. Just Recorded A 6.9% EPS Beat: Here's What Analysts Are Forecasting Next

Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Mar 20
Here's Why Qiagen (NYSE:QGEN) Can Manage Its Debt Responsibly

Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Feb 13
Calculating The Intrinsic Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

Jan 23
Qiagen N.V.'s (NYSE:QGEN) Price Is Out Of Tune With Earnings

These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

Dec 08
These 4 Measures Indicate That Qiagen (NYSE:QGEN) Is Using Debt Reasonably Well

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Oct 24
An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 41% Undervalued

Qiagen: No Upsides Slated In FY'23 In Core Business Lines, Reiterate Hold

Sep 09

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Sep 04
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jul 17
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen: Major Asset Growth Needed In Post-Covid World

Jun 22

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

May 23
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Apr 18
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Feb 15
Qiagen (NYSE:QGEN) Seems To Use Debt Quite Sensibly

Qiagen: Strong Q4, Derisked Portfolio, Fairly Valued

Feb 14

Qiagen Non-GAAP EPS of $0.53, revenue of $498M, FY23 guidance initiated

Feb 07

If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Jan 18
If EPS Growth Is Important To You, Qiagen (NYSE:QGEN) Presents An Opportunity

Qiagen, Helix partner to advance NGS companion diagnostics in hereditary diseases

Jan 06

A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Jan 04
A Look At The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen's test gets FDA nod for companion diagnostic to Mirati's cancer drug Krazati

Dec 13

Qiagen Non-GAAP EPS of $0.53 beats by $0.08, revenue of $500M beats by $17.91M

Nov 07

We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Oct 31
We Think Qiagen (NYSE:QGEN) Can Stay On Top Of Its Debt

Qiagen stock down after BHF downgrades rating to Neutral

Oct 10

Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Oct 04
Calculating The Fair Value Of Qiagen N.V. (NYSE:QGEN)

Qiagen to develop companion diagnostic for Neuron23's Parkinson's disease drug candidate

Sep 14

Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Aug 25
Does Qiagen (NYSE:QGEN) Deserve A Spot On Your Watchlist?

Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Jul 28
Is Qiagen (NYSE:QGEN) Using Too Much Debt?

Analyse CEO-vergoeding

Hoe is Thierry Bernard's beloning veranderd ten opzichte van Qiagen's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Jun 30 2024n/an/a

US$73m

Mar 31 2024n/an/a

US$337m

Dec 31 2023US$2mUS$979k

US$341m

Sep 30 2023n/an/a

US$485m

Jun 30 2023n/an/a

US$337m

Mar 31 2023n/an/a

US$353m

Dec 31 2022US$10mUS$950k

US$423m

Sep 30 2022n/an/a

US$488m

Jun 30 2022n/an/a

US$539m

Mar 31 2022n/an/a

US$563m

Dec 31 2021US$2mUS$900k

US$513m

Sep 30 2021n/an/a

US$311m

Jun 30 2021n/an/a

US$480m

Mar 31 2021n/an/a

US$449m

Dec 31 2020US$2mUS$900k

US$359m

Sep 30 2020n/an/a

US$191m

Jun 30 2020n/an/a

US$14m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$650k

-US$41m

Compensatie versus markt: De totale vergoeding ($USD 1.99M ) Thierry } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.87M ).

Compensatie versus inkomsten: De vergoeding van Thierry is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Thierry Bernard (60 yo)

5.1yrs

Tenure

US$1,991,874

Compensatie

Mr. Thierry Bernard serves as Director of Neogen Corporation since November 01, 2024. He has been Chief Executive Officer of QIAGEN N.V. since March 2020 and also serves as its Member of Management Board s...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Thierry Bernard
CEO, MD & Member of Management Board5.1yrsUS$1.99m0.14%
$ 14.0m
Roland Sackers
CFO, MD & Member of Management Board20.8yrsUS$1.07m0.19%
$ 18.3m
Antonio Santos
Senior VP & Head of Global Operations2.6yrsgeen gegevensgeen gegevens
John Gilardi
Vice President of Corporate Communications & Investor Relations14.1yrsgeen gegevensgeen gegevens
Stephany Foster
Senior VP & Head of Human Resources5.1yrsgeen gegevensgeen gegevens
Thomas Schweins
Senior Vice President of Life Science Business Area6.8yrsgeen gegevensgeen gegevens
Thomas Theuringer
Senior Director & Head of External Communicationsno datageen gegevensgeen gegevens
Jean-Pascal Viola
Senior VP & Head of Corporate Strategy and Business Development9.5yrsgeen gegevensgeen gegevens
Jonathan Sheldon
Senior VP & Head of the QIAGEN Digital Insights Business Area6.8yrsgeen gegevensgeen gegevens
Fernando Beils
Senior VP & Head of the Molecular Diagnostics Business Areano datageen gegevensgeen gegevens
Nitin Sood
Senior VP & Head of the Life Sciences Business Areano datageen gegevensgeen gegevens

6.8yrs

Gemiddelde duur

52yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van QGEN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.8 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Stephen Rusckowski
Independent Member of Supervisory Board1.6yrsUS$46.07k0.000010%
$ 970.1
Metin Colpan
Independent Member of the Supervisory Board & Vice Chair of the Scientific Advisory Board20.8yrsUS$86.50k0.080%
$ 7.7m
Elizabeth Tallett
Independent Member of the Supervisory Board13.4yrsUS$101.50k0.022%
$ 2.1m
Eva Pisa
Independent Member of the Supervisory Board2.4yrsUS$68.50kgeen gegevens
Lawrence Rosen
Independent Chairman of Supervisory Board11.4yrsUS$188.50k0.0067%
$ 650.9k
Toralf Haag
Independent Member of the Supervisory Board3.8yrsUS$82.50k0.0012%
$ 114.5k
Elaine Mardis
Independent Member of the Supervisory Board10.4yrsUS$79.50k0.0018%
$ 178.5k
Peter Kaspar
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Ross Levine
Independent Member of the Supervisory Board & Chair of the Scientific Advisory Board8.8yrsUS$68.50k0.0075%
$ 730.5k
Patrice Nordmann
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Neville Sanjana
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens
Sarah Polonius-Teichmann
Member of the Scientific Advisory Boardno datageen gegevensgeen gegevens

9.6yrs

Gemiddelde duur

67yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van QGEN wordt beschouwd als ervaren (gemiddelde ambtstermijn 9.6 jaar).